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Background: The purpose of this study was to identify parameters capable of predicting the deterioration of
hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma.
Methods: Between March 2006 and February 2012, 72 patients were eligible for this study. All patients received
hypofractionated radiotherapy using the TomoTherapy Hi-Art (TomoTherapy, Madison, WI, USA) at Seoul St. Mary's
Hospital and Incheon St. Mary's Hospital, the Catholic University of Korea. The radiation dose was a median 50 Gy
(range: 40–50 Gy) in 10 fractions to 95% of the planning target volume. Radiation-induced hepatic toxicity was
defined as an increase of at least 2 points in the Child-Pugh (CP) score within 3 months after completion of helical
tomotherapy.
Results: An increase of at least 2 points in the CP score occurred in 32 of the 72 patients (44.4%). Multivariate
logistic regression analysis revealed that pretreatment CP class and V15Gy were significant parameters associated
with an increase in CP score (p = 0.009 and p < 0.001, respectively). The area under receiver operating characteristic
curve was 0.863 for V15Gy (p < 0.001). For V15Gy, with a cutoff value of 43.2%, the accuracy was 0.806 (58/72) with a
sensitivity of 0.938 and a specificity of 0.725.
Conclusions: An increase of at least 2 points in the CP score is a radiation dose-limiting factor, and the non-target
normal liver receiving a dose more than 15 Gy (V15Gy) should be <43.2% to reduce the risk of the deterioration of
hepatic function.
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Hepatocellular carcinoma (HCC), which is one of the
most common malignant carcinomas worldwide, is a
fatal disease that might cause death with severe compli-
cation if treated improperly [1,2]. Although a surgical
resection is considered the treatment of choice, many
patients are either inoperable or the tumor is unresect-
able at the time of diagnosis. In these cases, transarterial* Correspondence: hsjang11@catholic.ac.kr
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reproduction in any medium, provided the orchemoembolization (TACE), percutaneous ethanol injec-
tion (PEI), and radiofrequency ablation (RFA) have been
used [3-5]. In contrast, radiotherapy (RT) had not been
widely used for the treatment of HCC because of the low
dose of radiation tolerable for the entire liver, which was
not effective for tumor control [6,7]. However, recently
reported studies showed that partial volume irradiation of
the liver is feasible and a useful tool for the treatment of
HCC within an acceptable range of hepatic toxicity [8-11].
In the use of RT for the treatment of HCC, radiation-
induced hepatic toxicity (RIHT) is considered a significant
dose-limiting factor because of its potential to cause liver. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.














































Systemic CTx 3 4.2
Radiation dose
40 Gy/10 fxs 6 8.3
Table 1 Patient’s characteristics (Continued)
45 Gy/10 fxs 10 13.9
50 Gy/10 fxs 56 77.8
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status; HBV hepatitis B virus; HCV hepatitis C virus; PVTT portal vein tumor
thrombosis; AFP alpha-fetoprotein; AJCC American Joint Committee on Cancer;
TACE transcatheter arterial chemoembolization; RFA radiofrequency ablation;
PEI percutaneous ethanol injection; RT radiotherapy; CTx chemotherapy; fxs
fractions.
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ing a parameter that can predict, and thus, prevent RIHT.
To date, several reports investigating parameters capable of
predicting RIHT have been recently published [12-17];
however, these reports are based on clinical data from
3-dimensional conformal radiotherapy (3D-CRT). When
compared with 3D-CRT, helical tomotherapy is an
advanced technique that can provide a high dose of radi-
ation to the target volume, while reducing the dose to the
surrounding normal tissues. But, low to moderate dose of
radiation distributed to a much wider region of the
normal liver could affect the incidence of RIHT.
Here, we evaluated RIHT reflecting the deterioration
of hepatic function in advanced HCC patients treated
with helical tomotherapy and identified a parameter
capable of predicting RIHT.
Methods
Patients
The inclusion criteria for this study were as follows:
1) unresectable locally advanced HCC, 2) prior treat-
ment by hypofractionated helical tomotherapy with a
curative aim, 3) a radiation dose of 40–50 Gy in 10 frac-
tions, 4) 2 or more laboratory studies within 3 months
after the completion of helical tomotherapy, 5) 1 or more
radiologic studies within 3 months after the completion of
helical tomotherapy, and 6) no intrahepatic disease
progression within 3 months after the completion of
helical tomotherapy.
Between March 2006 and February 2012, 72 patients
were eligible for this study. All the patients received
hypofractionated RT using the TomoTherapy Hi-Art
(TomoTherapy, Madison, WI, USA) at Seoul St. Mary's
Hospital and Incheon St. Mary's Hospital, the Catholic
University of Korea. The patients' clinical and dosimetric
data were retrospectively collected following Institutional
Review Board approval. The patients' characteristics are
shown in Table 1.
Prior to helical tomotherapy, 65 patients (90.3%) were
treated with other locoregional treatments such as
TACE, RFA, PEI, and surgery. Within 3 months after the
completion of helical tomotherapy, TACE was performed
in 41 patients (56.9%) (median: 1 time, average: 1.5 times,
range: 1–3 times). In addition, RFA and PEI were
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chemotherapy was performed in 3 patients (4.2%).
Target volume and treatment
The gross tumor volume (GTV) was defined as the
tumor volume that was enhanced in the arterial phase
and diluted in the delayed phase of computed tomog-
raphy (CT) scan. The planning target volume (PTV) was
generated by adding 5–15 mm to the GTV in 52 of the
72 patients, facilitating asymmetric margin expansion to
reduce irradiation to the stomach, duodenum, and small
intestine. In the remaining 20 of 72 patients, 4-dimensional
CT (4D-CT) was performed to generate the internal target
volume to compensate for respiratory-induced liver
movement because of the installation of 4D-CT in
March 2009 at Seoul St. Mary’s hospital and in March
2011 at Incheon St. Mary’s hospital. Organs at risks
such as the total liver, non-target normal liver (NTNL),
stomach, duodenum, intestine, kidney, and spinal cord
were also contoured for evaluation of the irradiated dose.
NTNL volume was the total liver volume minus PTV.
The prescribed radiation dose was a median 50 Gy
(range: 40–50 Gy) in 10 fractions to 95% of the PTV. Prior
to the actual beam delivery, megavoltage cone-beam CT
was performed at the time of every treatment session. Each
patient’s set-up and position were corrected with automated
image registration, and the anatomical accuracy was always
evaluated by a radiation oncologist.
Evaluation of the radiation-induced hepatic toxicity
RIHT was defined as an increase of at least 2 points in
the Child-Pugh (CP) score within 3 months after the
completion of helical tomotherapy. CP score, which is
calculated on the basis of the serum bilirubin and albumin
levels, prothrombin time (PT), and the presence and degree
of ascites or encephalopathy, is an assessment of the sever-
ity of hepatic function. Thus, an increase in CP score
reflects the deterioration of hepatic function [18].
During helical tomotherapy, patients were seen weekly
by a physician to evaluate their complaints. After comple-
tion of helical tomotherapy, patients were followed-up
every 1–2 months. At every visit, physical examinations
and blood tests were performed to assess hepatic toxicity.
Levels of aspartate transaminase (AST), alanine transamin-
ase (ALT), alkaline phosphatase (ALP), serum albumin,
total bilirubin and PT were examined. Ascites and hepatic
encephalopathy were also evaluated.
Parameters for predicting RIHT
The clinical parameters analyzed were gender, age, Eastern
Cooperative Oncology Group (ECOG) performance status,
pretreatment CP class, American Joint Committee on
Cancer (AJCC) stage, pretreatment level of alpha-
fetoprotein (AFP) and the presence or absence of hepatitis,liver cirrhosis, portal vein tumor thrombosis (PVTT) and
previous treatments.
The dosimetric parameters analyzed were PTV, mean dose
of NTNL, the percentage of NTNL volume receiving >5
Gy (V5Gy), >10 Gy (V10Gy), >15 Gy (V15Gy), >20 Gy (V20Gy),
>25 Gy (V25Gy), >30 Gy (V30Gy), >35 Gy (V35Gy), and >40 Gy
(V40Gy).
Statistical analyses
Pearson's chi-square and the independent t-test were
used for univariate analysis of the clinical parameters
associated with RIHT. Binary logistic regression analysis
was used for univariate analysis of dosimetric parameters
associated with RIHT. Multivariate analysis was per-
formed using the logistic regression model containing all
significant variables according to univariate analysis (se-
lection: stepwise forward). The receiver operating char-
acteristic (ROC) curve was used to estimate the
significant dosimetric parameters. All statistical analyses
were performed using SPSS ver. 12.0 (SPSS Institute,
Chicago, Illinois) and a p value of <0.05 was considered
significant.
Results
Clinical and dosimetric parameters associated with an
increase in CP score
An increase of at least 2 points in the CP score occurred
in 32 of 72 patients (44.4%) within 3 months after
completion of helical tomotherapy. Univariate analysis
results showing the associations between clinical para-
meters and the increased the CP score are summarized in
Table 2. Age, gender, pretreatment level of AFP, and the
presence of hepatitis and/or liver cirrhosis did not contrib-
ute to an increase in CP score after helical tomotherapy.
In addition, previous treatments and treatments given
after completion of helical tomotherapy did not contribute
to an increase in CP score (p = 0.374 and 0.394, respect-
ively). In contrast, AJCC stage, the presence of PVTT, and
pretreatment CP class were significantly associated with
an increase in the CP score after helical tomotherapy
(p = 0.021, 0.037, and 0.006, respectively).
Univariate analysis of the associations between the
dosimetric parameters and the increase in CP score
showed that PTV, mean dose of NTNL, V5Gy, V10Gy,
V15Gy, V20Gy, V25Gy, V30Gy and V35Gy were significantly
associated with an increase in the CP score (Table 3).
Multivariate logistic regression analysis confirmed that
pretreatment CP class and V15Gy were significant para-
meters associated with an increase in the CP score
(p = 0.009 and p<0.001, respectively). As shown in Figure 1,
the area under the ROC curve (AUC) was 0.863 for V15Gy (p<
0.001), indicating that V15Gy with a cutoff value of 43.2% was an
appropriate value to predict an increase in the CP score. An in-
crease in the CP score was observed in 2 of 30 patients (6.7%)
Table 2 Clinical parameters in patients with or without an
increase in Child-Pugh score ≥ 2
































Treatment after RT 0.394
No 19 12
Yes 21 20
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status; AFP alpha-fetoprotein; LC liver cirrhosis; PVTT portal vein tumor
thrombosis; CP class Child-Pugh class; AJCC American Joint Committee on
Cancer; RT radiotherapy.
*Significant parameters in univariate analysis.
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V15Gy of >43.2%. For V15Gy, with a cutoff value of 43.2%,
the accuracy was 0.806 (58/72) with a sensitivity of 0.938
and a specificity of 0.725.
Normal liver dose-volume histogram (DVH) reflecting the
risk of the deterioration of hepatic function
Close correlations were demonstrated between dosimetric
parameters that were shown to be significant in theunivariate analysis (V5Gy vs. V10Gy, r = 0.890, p < 0.001;
V10Gy vs. V15Gy, r = 0.936, p < 0.001; V15Gy vs. V20Gy,
r = 0.945, p < 0.001; V20Gy vs. V25Gy, r = 0.962, p < 0.001;
V25Gy vs. V30Gy, r = 0.916, p < 0.001; V30Gy vs. V35Gy,
r = 0.904, p < 0.001). Although V15Gy was the only signifi-
cant dosimetric parameter found in multivariate analysis,
other parameters (V5Gy, V10Gy, V20Gy, V25Gy, V30Gy and
V35Gy) that were shown to be statistically significant in
univariate analysis also demonstrated similar relationship
patterns in their estimated probability curves (Figure 2).
Additionally, the area under the ROC curve of each of these
parameters was regarded as a good value with statistical
significance (Table 3). From these curves, the values
indicating a 10%, 20% and 30% risk of an increase in the
CP score were obtained. These values correspond to the
normal liver DVH reflecting the risk of the deterioration of
hepatic function. It could provide a treatment planning
guideline to reduce the risk of developing the deterioration
of hepatic function (Figure 3).Discussion
Ablation, chemoembolization, and RT have been used
for the treatment of unresectable locally advanced HCC.
Because RT alone cannot achieve a complete response in
most cases, other locoregional treatments, such as
TACE, RFA, and PEI, have been used repeatedly prior to
or after RT. After completion of RT, transient elevation of
hepatic enzymes such as AST, ALT, and ALP commonly
occurs, but, in many cases, these kinds of hepatic toxicities
are recovered in a few months [14]. However, if hepatic
function deteriorates because of radiation, other necessary
treatments cannot be performed in a timely manner. Since
no specific treatment for this condition exists except
conservative care, it is also important to reduce the
development of the deterioration of hepatic function. Thus,
it is important to identify a parameter that can predict the
deterioration of hepatic function and to develop a plan for
RT using the parameter and its values.
The relationship between the radiation dose to liver
volume and the incidence of hepatic toxicities has been
studied previously [12-15,17]. Radiation-induced liver
disease (RILD) is a traditionally accepted concept of
hepatic toxicity [7]. In the past, classic RILD was a serious
manifestation of hepatic toxicity caused by irradiation of
30–35 Gy to the entire liver. However, the incidence of
classic RILD has been lowered, since partial volume irradi-
ation has become more common. Other authors have
reported the parameters predicting the non-classic RILD
or the elevation of hepatic enzymes ≥ grade 2 or 3 accord-
ing to Radiation Therapy Oncology Group toxicity criteria
or Common Terminology Criteria for Adverse Events
(CTCAE) and their cut-off values to present a guideline for
radiation planning [12,14,15,17].





p value (95% CI) ROC curve
AUC p value
PTV (cm3) 103.8 ± 102.8 227.1 ± 193.5 0.004 (1.002-1.011) 0.741 <0.001
Mean dose of NTNL (Gy) 14.9 ± 4.1 20.2 ± 3.2 <0.001 (1.209-1.708) 0.839 <0.001
V5Gy 76.6 ± 17.5 91.2 ± 7.6 0.001 (1.040-1.153) 0.765 <0.001
V10Gy 57.1 ± 19.1 79.2 ± 10.7 <0.001 (1.048-1.140) 0.830 <0.001
*V15Gy 39.2 ± 14.8 61.3 ± 11.9 <0.001 (1.064-1.180) 0.863 <0.001
V20Gy 27.1 ± 11.0 44.0 ± 11.8 <0.001 (1.069-1.199) 0.852 <0.001
V25Gy 19.4 ± 8.6 30.5 ± 10.1 <0.001 (1.062-1.204) 0.804 <0.001
V30Gy 14.8 ± 7.6 21.6 ± 8.3 0.002 (1.040-1.187) 0.738 0.001
V35Gy 10.5 ± 6.2 15.4 ± 7.1 0.006 (1.033-1.205) 0.706 0.003
V40Gy 7.2 ± 5.1 9.9 ± 5.1 0.053 (0.999-1.190) - -
Abbreviations: CI confidence interval; ROC receiver operating characteristic; AUC area under curve; PTV planning target volume; NTNL non-target normal liver.
*Significant parameter on multivariate logistic regression analysis.
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First, the presence or absence of an increase of at least 2
points in the CP score as an end-point of RIHT was
used for analysis. A few authors have analyzed the
elevation of hepatic enzymes (AST, ALT and ALP) as
end points to find significant parameters that predict
hepatic toxicities [12-15,17]. Kim et al. showed that the
elevation of hepatic enzymes was transient and recovered
within a median of 2 months after the completion of RT
[14]. However, Furuse et al. showed that hypoalbuminemia,
hyperbilirubinemia and ascites were important adverse
hepatic events that occur after the application of RT to treat
advanced HCC, and these events seriously affected survival
[19]. An albumin, bilirubin and ascites were used toFigure 1 Receiver operating characteristic curve for V15Gy.calculate the CP score. In our previous study, the progres-
sion of CP class was analyzed as a useful radiation dose-
limiting factor predicting the deterioration of hepatic func-
tion, whereas the elevation of hepatic enzymes according to
the CTCAE scale was inappropriate as a useful end point
[20]. Liaw et al. also used an increase of at least 2 points in
the CP score to evaluate the deterioration of hepatic func-
tion in patients who were treated with lamivudine [18].
Therefore, the CP score is appropriate for the assessment
of hepatic function, and an increase of at least 2 points in
the CP score should be considered the dose-limiting factor.
Another difference between our study and previous
studies is that only patients treated with helical tomother-
apy were included in the present study. Previous studies
regarding the dosimetric parameters predicting hepatic
toxicity were based on the data from 3D-CRT. The
planning and delivery method of helical tomotherapy is
different from that of 3D-CRT. Because helical tomother-
apy is delivered continuously from all angles around the
patient via a ring gantry, in which the linear accelerator is
mounted, a low to moderate radiation dose is delivered to
a much wider region of liver. Because of this characteristic,
the parameter and its cut-off value could be different
between 3D-CRT and helical tomotherapy. According to
Kim et al., V30 was demonstrated as a significant parameter
in patients treated with conventional fractionated RT [14],
and according to Liang et al., V20 was a significant param-
eter in patients treated with hypofractionated RT (4–6 Gy
per fraction) [16]. In our study, a significant parameter is
V15Gy, which is a parameter that corresponds to lower
doses than those of above studies. The cut-off value of
43.2% for V15Gy in our study is lower than that in the above
studies (60% for V30 in the study of Kim et al. and 48.5%
for V20 in the study of Ling et al.). This result is probably
because of the characteristic planning and delivery method
of helical tomotherapy and indicates that, to reduce the
Figure 2 The estimated probability of an increase in CP score for V5Gy, V10Gy, V15Gy, V20Gy, V25Gy, V30Gy, and V35Gy.
Figure 3 The normal liver dose-volume histogram indicating a 10%, 20%, and 30% risk of an increase in CP score.
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of normal liver should be preserved from a low to moderate
dose of radiation.
The third differences between our study and previous
studies is that V15Gy was confirmed the only significant
dosimetric parameter in multivariate analysis. However,
because of the significant correlations between dosimetric
parameters shown in univariate analysis, consideration of
the values of these parameters could be helpful in the
treatment planning phase. Based on the estimated
probability curves of V5Gy, V10Gy, V15Gy, V20Gy, V25Gy,
V30Gy, and V35Gy, which were statistically significant in
univariate logistic and ROC curve analyses, we presented
the normal liver DVH indicating a 10%, 20%, and 30% risk
of the deterioration of hepatic function (Figure 3). This
curve could be used as a reference tolerance curve to
evaluate treatment plans.
In conclusion, an increase of at least 2 points in the
CP score is a radiation dose-limiting factor, and the non-
target normal liver receiving a dose more than 15 Gy
(V15Gy) should be <43.2% to reduce the risk of the
deterioration of hepatic function. Moreover, the proposed
normal liver DVH could be useful as a reference curve to
evaluate the dose to the liver.
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